Education
About Us
Working with TipRanks
Follow Us
TransCode Therapeutics (RNAZ)
NASDAQ:RNAZ
RESEARCH TOOLSreports
RNAZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.14 - $924.38
Previous CloseN/A
Volume52.57K
Average Volume (3M)64.03K
Market Cap
$6.64M
Enterprise Value$685.41M
Total Cash (Recent Filing)$11.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.16
Next Earnings
Mar 28, 2025EPS Estimate
-105.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.61
Shares Outstanding833,620
10 Day Avg. Volume31,047
30 Day Avg. Volume64,030
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)87.72
Price to Sales (P/S)0.00
P/FCF Ratio-17.92
Enterprise Value/Market Cap103.16
Enterprise Value/Revenue455.03
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.41
Forecast
1Y Price Target
$10.00Price Target Upside25.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
TransCode Therapeutics News
PremiumCompany Announcements
TransCode Therapeutics Announces 2025 Annual Meeting Date
PremiumCompany Announcements
TransCode Therapeutics Faces Nasdaq Delisting Risk
PremiumCompany Announcements
TransCode Therapeutics Announces Reverse Stock Split
PremiumCompany Announcements
TransCode Therapeutics Announces Reverse Stock Split Approval
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe safety review committee has approved opening of Cohort 4 in the Phase 1 trial evaluating TTX-MC138 in advanced/metastatic solid tumors, based on favorable safety observed in previous cohorts.
Financial PerformanceThe company ended 2024 with $5.8M in cash and equivalents, excluding a recent $8.8M equity raise, indicating strong financial positioning.
Strategic PartnershipsThe company is engaged in potential pipeline partnerships, indicating strategic growth opportunities following the presentation of initial data.
Bears Say
Investor SentimentInvestors may be disappointed with not seeing initial responses.
Operating ExpensesIn 4Q24, the company reported operating expenses of $5.1M, significantly higher than 3Q24, likely due to costs related to dose escalation in the Phase 1 trial of TTX-MC138.
Risk And Safety ConcernsRisks include safety signals emerging with any of the company's clinical or preclinical programs, as well as possible lower-than-expected efficacy from clinical programs.
Options Prices
Currently, No data available
---
Ownership Overview
6.76%
Insiders
0.56%
Mutual Funds
― Other Institutional Investors
91.56% Public Companies and Individual Investors
RNAZ FAQ
What was TransCode Therapeutics’s price range in the past 12 months?
TransCode Therapeutics lowest stock price was $6.14 and its highest was $924.38 in the past 12 months.
What is TransCode Therapeutics’s market cap?
TransCode Therapeutics’s market cap is $6.64M.
When is TransCode Therapeutics’s upcoming earnings report date?
TransCode Therapeutics’s upcoming earnings report date is Mar 28, 2025 which is 93 days ago.
How were TransCode Therapeutics’s earnings last quarter?
TransCode Therapeutics released its earnings results on Nov 11, 2024. The company reported -$5.28 earnings per share for the quarter, beating the consensus estimate of -$16.17 by $10.89.
Is TransCode Therapeutics overvalued?
According to Wall Street analysts TransCode Therapeutics’s price is currently Undervalued.
Does TransCode Therapeutics pay dividends?
TransCode Therapeutics does not currently pay dividends.
What is TransCode Therapeutics’s EPS estimate?
TransCode Therapeutics’s EPS estimate is -105.93.
How many shares outstanding does TransCode Therapeutics have?
TransCode Therapeutics has 833,620 shares outstanding.
What happened to TransCode Therapeutics’s price movement after its last earnings report?
TransCode Therapeutics reported an EPS of -$5.28 in its last earnings report, beating expectations of -$16.17. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of TransCode Therapeutics?
Currently, no hedge funds are holding shares in RNAZ
TransCode Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (25.47% Upside)
$10.00 (25.47% Upside)
Blogger Sentiment
Bullish
RNAZ Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.14%
12-Months-Change
Fundamentals
Return on Equity
-342.99%
Trailing 12-Months
Asset Growth
80.98%
Trailing 12-Months
Company Description
TransCode Therapeutics
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Technical Analysis
Palatin Technologies
―
Evogene
―
MetaVia
―
Silexion Therapeutics
―
Lipella Pharmaceuticals, Inc.
―